Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis

Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis

ABSTRACT Objective: To explore the feasibility of 68Ga-PSMA PET/CT in diagnosing primary prostate cancer. Materials and Methods: Embase, PubMed and Cochrane Library databases were searched for studies published before July 2020. The studies that used 68Ga-PSMA PET/CT for detecting primary prostate...

Full description

Bibliographic Details
Main Authors:	Xianwen Hu, Yan Wu, Peiqing Yang, Ju Wang, Pan Wang, Jiong Cai
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2022-11-01
Series:	International Brazilian Journal of Urology
Subjects:	Prostate-Specific Antigen Prostatic Neoplasms Positron Emission Tomography Computed Tomography
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382022000600891&tlng=en

Similar Items

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2024-01-01)

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends
by: Cristian Udovicich, et al.
Published: (2017-12-01)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
by: Henry H. Woo, et al.
Published: (2023-01-01)

A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?
by: Jianliang Liu, et al.
Published: (2024-01-01)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
by: Timothy N. Kwan, et al.
Published: (2021-06-01)

Gene’s expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study
by: Matteo Bauckneht, et al.
Published: (2023-01-01)

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
by: Paulina Cegla, et al.
Published: (2022-01-01)

Restaging the Biochemical Recurrence of Prostate Cancer with [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
by: Aloÿse Fourquet, et al.
Published: (2021-03-01)

A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies
by: Gideon Ptasznik, et al.
Published: (2023-04-01)

Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients
by: Nuo Yi, et al.
Published: (2023-03-01)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
by: Cristian Udovicich, et al.
Published: (2022-10-01)

Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
by: Dennie Meijer, et al.
Published: (2024-03-01)

Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure
by: Dong-Yun Kim, et al.
Published: (2023-06-01)

Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)
by: Tobias Hölscher, et al.
Published: (2022-04-01)

Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era?
by: Joris G. Heetman, et al.
Published: (2022-10-01)

Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis
by: Yi Zhao, et al.
Published: (2022-07-01)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
by: Brian D. Kelly, et al.
Published: (2023-07-01)

Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens
by: Christopher Darr, et al.
Published: (2023-08-01)

Accuracy of PET-choline in nodal staging of localized very high-risk prostate cancer
by: Nuno Dias, et al.
Published: (2022-12-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Sangwon Han, et al.
Published: (2021-04-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
by: Jiaxian Chen, et al.
Published: (2022-08-01)

The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen
by: Hee Ju Cho, et al.
Published: (2014-12-01)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
by: Lorenzo Cereser, et al.
Published: (2023-08-01)

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer
by: Luca Filippi, et al.
Published: (2021-03-01)

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy
by: Yong Hyun Park, et al.
Published: (2014-03-01)

A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
by: Mike Allan Mortensen, et al.
Published: (2018-12-01)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
by: Peter Ka-Fung Chiu, et al.
Published: (2016-09-01)

A Retrospective Comparative Study of Sodium Fluoride Na<sup>18</sup>F-PET/CT and <sup>68</sup>Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis
by: Kalevi Kairemo, et al.
Published: (2022-11-01)

Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy
by: Ernani L. Rhoden, et al.
Published: (2003-04-01)

[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
by: Florian Rosar, et al.
Published: (2024-02-01)

Nadir prostate-specific antigen as a prognostic factor of 10-year cancer-specific survival of prostate cancer patients with bone metastases
by: Chi-Feng Hung, et al.
Published: (2022-01-01)

CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY
by: Zujaja Hina Haroon, et al.
Published: (2022-03-01)

The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography for non-prostate cancer-related pathology: A single centre retrospective study
by: Anthony Franklin, et al.
Published: (2024-01-01)

Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
by: Rachel M. Glicksman, et al.
Published: (2023-06-01)

Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
by: Yan Jin, et al.
Published: (2022-05-01)

Relationship Between SUVmax and ADC Values of Metastatic Lymph Nodes Detected by Ga-68 PSMA PET/MR in Prostate Cancer Patients
by: Fuad Aghazada, et al.
Published: (2022-01-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach
by: Francesco Dondi, et al.
Published: (2024-03-01)